- Home
- PCRX vs DNA Comparison
PCRX vs DNA Comparison
Compare PCRX & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- DNA
- Stock Information
- Founded
- PCRX 2006
- DNA 2008
- Country
- PCRX United States
- DNA United States
- Employees
- PCRX N/A
- DNA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- DNA Health Care
- Exchange
- PCRX Nasdaq
- DNA Nasdaq
- Market Cap
- PCRX 604.7M
- DNA 542.6M
- IPO Year
- PCRX 2011
- DNA N/A
- Fundamental
- Price
- PCRX $18.98
- DNA $10.10
- Analyst Decision
- PCRX Buy
- DNA Hold
- Analyst Count
- PCRX 10
- DNA 6
- Target Price
- PCRX $26.60
- DNA $37.80
- AVG Volume (30 Days)
- PCRX 933.0K
- DNA 1.5M
- Earning Date
- PCRX 11-06-2024
- DNA 11-12-2024
- Dividend Yield
- PCRX N/A
- DNA N/A
- EPS Growth
- PCRX N/A
- DNA N/A
- EPS
- PCRX N/A
- DNA N/A
- Revenue
- PCRX $694,957,000.00
- DNA $217,951,000.00
- Revenue This Year
- PCRX $4.94
- DNA N/A
- Revenue Next Year
- PCRX N/A
- DNA N/A
- P/E Ratio
- PCRX N/A
- DNA N/A
- Revenue Growth
- PCRX 4.40
- DNA N/A
- 52 Week Low
- PCRX $11.16
- DNA $5.26
- 52 Week High
- PCRX $35.95
- DNA $74.00
- Technical
- Relative Strength Index (RSI)
- PCRX 54.07
- DNA 56.46
- Support Level
- PCRX $18.73
- DNA $10.48
- Resistance Level
- PCRX $20.34
- DNA $9.92
- Average True Range (ATR)
- PCRX 1.13
- DNA 1.14
- MACD
- PCRX -0.03
- DNA -0.12
- Stochastic Oscillator
- PCRX 64.09
- DNA 47.49
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.